PULM News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PU

Mkt Cap

$5.1M

Volume

14.85K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The investigations concern whether shareholders are receiving fair consideration in these transactions, with concerns that insiders may benefit disproportionately and deal terms may prevent superior competing offers.GlobeNewswire Inc. · Jul 10, 2026

Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation ForumEos SENOLYTIX presented preclinical data for its lead candidate PTC-2105, a mitochondrial-targeted geropeptide showing improvements in body composition with lean mass gains and fat reduction without the muscle loss associated with GLP-1 therapies. The company also announced a merger agreement with Pulmatrix, Inc., expected to close in Q3 2026 under the new ticker symbol MTXL. Preclinical studies demonstrated extended survival in aged mice and prevention of age-related decline.GlobeNewswire Inc. · Jun 5, 2026

Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock NowPulmatrix, Inc. (PULM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.Zacks Investment Research · Sep 11, 2023

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue EstimatesHOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.76% and 24.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Aug 10, 2023

UniQure (QURE) Reports Q2 Loss, Misses Revenue EstimatesuniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Aug 1, 2023

Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving PremarketGainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading. Vaccitech plc (NASDAQ: VACC) shares rose 25% to $5.89 in pre-market trading. Vaccitech recently posted Q2 earnings of $0.41 per share. AIM ImmunoTech Inc. (NYSE: AIM) rose 23.8% to $0.87 in pre-market trading. AIM Immunotech recently reported commencement of Phase 2 study of Ampligen for the treatment of pancreatic cancer. Snowflake Inc. (NYSE: SNOW) rose 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance. Allarity Therapeutics, Inc. (NASDAQ: ALLR) rose 16.4% to $1.42 in pre-market trading after gaining 5% on Wednesday. Ladenburg Thalmann recently downgraded Allarity Therapeutics from Buy to Neutral. FREYR Battery (NYSE: FREY) rose 14.7% to $12.14 in pre-market trading. FREYR Battery entered into strategic partnership with Hana Technology. Athersys, Inc. (NASDAQ: ATHX) rose 13.4% to $0.2029 in pre-market trading. Athersys recently reported closing of $12 million registered direct offering. ATRenew Inc. (NYSE: RERE) rose 10.6% to $3.77 in pre-market trading after jumping 19% on Wednesday. ATRenew posted Q2 loss of $0.01 per share. Pulmatrix, Inc.(NASDAQ: PULM) rose 9.6% to $5.92 in pre-market trading after jumping around 18% on Wednesday. Pulmonx recently said it sees FY22 sales of $55 million to $60 million. Autodesk, Inc. (NASDAQ:Benzinga · Aug 25, 2022

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue EstimatesMerus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2022

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue EstimatesArbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 5, 2022

Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue EstimatesPulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Nov 10, 2021

Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleasePulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · Nov 4, 2021

PU

PULMPulmatrix, Inc. Common Stock

PULM

Pay with—

Available Balance0.00

Your PositionYou don't own any PULM yet.

Related Tickers

Earnings